Related Experiment Video
Updated: Jan 30, 2026

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Risk-Based Therapeutic Strategies
Jill Corre1, Hervé Avet-Loiseau
1From the IUC-Oncopole and CRCT INSERM U1037, Toulouse, France.
Abstract:
Although therapeutic strategies have been adapted to age and comorbidities of myeloma patients for a long time, all patients currently experiment the same treatment whatever their genomic risk. However, high-risk patients should benefit right now from the most efficient drugs combinations. Herein, we review and discuss how to optimally define risk to adapt treatment and why a modern multiparametric definition of genomic risk is urgently needed. Minimal residual disease status will probably also take a growing place in patient's management, including in treatment adaptation. We also discuss how next-generation sequencing will definitively represent an essential tool to manage risk-based therapeutic strategies. Finally, despite an explosive knowledge of myeloma molecular landscape, targeted therapy perspectives remain poor, with only few exceptions.
More Related Videos
Related Concept Videos
Relative Risk
Cardiovascular Drugs: Classification based on Therapeutic Indications
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Therapeutic Index
Therapeutic Communication
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
Persuasion Strategies

